19th June 2015
Launched in June and available through PSUK, Mylan Sirdupla™ is the first bioequivalent alternative to the market-leading Seretide® Evohaler® (salmeterol xinafoate/fluticasone propionate). Sirdupla is a daily maintenance pressurised metered-dose inhaler, offering the same ease of use that patients expect from their asthma therapy. It is available in 125/25mcg and 250/25mcg with 120 doses.
President of Mylan Europe Jacek Glinka says “the launch of Mylan’s Sirdupla™ broadens access to an important treatment option and offers a familiar pMDI device experience to UK asthma sufferers. Asthma is a widespread illness in the UK and we are committed to contributing to ease this burden on both patients and the NHS.”
For further information on this product please click here. You can also contact the PSUK dispensing support team on 01904 558350.
Click Here for the SIRDUPLA